ObjectiveTo investigate the effect of levosimendan combined with ivabradine hydrochloride on heart function, myocardial fibrosis markers and exercise tolerance in patients with chronic heart failure. MethodsA total of 70 patients with chronic heart failure admitted to our hospital from January 2018 to October 2019 were selected as the research subjects, and they were divided into two groups according to the random number method, with 35 cases in each group. The control group was treated with levosimendan, whereas patients in the observation group administrated levosimendan combined with ivabradine hydrochloride, for a fourteen-day treatment course. The clinical efficacy, levels of myocardial fibrosis markers, exercise tolerance and heart function were compared between the two groups. ResultsAfter a treatment of 14 days, compared with the control group, the observation group yielded a higher total effective rate of treatment (94.3% vs. 74.3%, P=0.022), lower levels in connective tissue growth factor (CTGF), carboxyterminal telopeptide of type Ⅰ collagen (ⅠCTP), laminin (LN), hyaluronic acid (HA) and N-terminal propeptide of type Ⅲ procollagen (PⅢNP), whereas longer or larger indicators in exercise time, exercise equivalence, anaerobic threshold (AT), and peak oxygen consumption (VO2max), a significantly higher left ventricular ejection fraction (LVEF), while a significantly lower B-type brain natriuretic peptide (BNP), with statistically significant differences (P＜0.05). ConclusionLevosimendan combined with ivabradine hydrochloride in the treatment of patients with chronic heart failure can effectively improve cardiac function, delay myocardial fibrosis, and improve exercise tolerance in patients.

无